HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unilever results

This article was originally published in The Rose Sheet

Executive Summary

Skin care sales up 8% in North America in third quarter due to strong sales of Dove and Suave bar soaps and Dove facial cloths, according to Unilever sales and earnings announcement Nov. 2. Consolidated personal care sales increased 9% during the quarter, led by Dove including introduction of Dove shampoo in Italy and Japan, Unilever states. Mass market gains were partially offset by decline in prestige fragrances. Firm lost approximately $54.3 mil. (€1=$.90) in prestige fragrance category in third quarter due to decline in consumer confidence, Unilever says. Ad support will continue for Nautica, BCBG and Truth, which are expected to drive growth. Total turnover for Q3 increased 13% to $12.27 bil., while net profit before exceptional items, amortization of goodwill and intangibles was up 5% to $952.3 mil...

You may also be interested in...



Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

US/India Operation Intercepts Unapproved Drugs, Drug/Device Products

Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.

Two Companies, Two BARDA Contracts, Two Approaches To Coronavirus

Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.

UsernamePublicRestriction

Register

RS009781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel